from Hybrids-Polypeptides for Drug Applications

Scientific publication - Journal Article uoadl:2959179 60 Read counter

Unit:
Department of Chemistry
Title:
from Hybrids-Polypeptides for Drug Applications
Languages of Item:
English
Abstract:
Recently, the explosion of progress of materials at the nanoscale level has paved the way for a new category of healthcare technologies termed nanomedicine. Nanomedicine involves materials at the nanometer level for products that can improve the currently used technologies for biomedical applications. While traditional therapeutics have allowed for limited control of their distribution in the body and clearing times, engineering at the nanoscale level has allowed for significant advances in biocompatibility, biodistribution, and pharmacokinetics. Among all materials, polymers have dominated the nanomedicine world, due to their ability to manipulate their properties by combining different materials in a wide variety of macromolecular architectures. The development of novel polymeric materials is guided by the goal of improving patient survival and quality of life by increasing the bioavailability of drug to the site of disease, targeting delivery to the pathological tissues, increasing drug solubility, and minimizing systemic side effects. Polymersomes (vesicles) are the only type of polymeric nanocarriers that can physically encapsulate at the same nanoparticle hydrophilic drugs in their aqueous interior and/or hydrophobic agents within their lamellar membranes. Polymersomes have been shown to possess superior biomaterial properties compared to liposomes, including greater stability and storage capabilities, as well as prolonged circulation time. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
Publication year:
2020
Authors:
Hermis Iatrou
Panagiota G. Fragouli
Dimitris Skourtis
Ioanna Stavropoulou
Publisher:
Springer US
Pages:
139--150
Keywords:
1,6 hexanediamine; doxorubicin; liposome; monomer; n,n dimethylformamide; nanocarrier; paclitaxel; poly(lysine) b poly(gamma benzyl d7 glutamate) b poly(lysine); polymer; polymersome; polypeptide; unclassified drug; antineoplastic agent; drug carrier; nanoparticle; peptide, acute toxicity; animal experiment; animal model; antineoplastic activity; controlled study; drug bioavailability; drug delivery system; drug solubility; human; human cell; in vitro study; mouse; nanopharmaceutics; nonhuman; pancreatic cancer cell line; pH; polymerization; chemical phenomena; chemistry; metabolism; pancreas tumor; pathology, Antineoplastic Agents; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Pancreatic Neoplasms; Peptides
Main subject category:
Science
DOI:
10.1007/978-1-0716-0920-0_11
The digital material of the item is not available.